Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
FcγRIIIa receptor interacts with androgen receptor and PIP5K1α to promote growth and metastasis of prostate cancer
Umeå universitet, Medicinska fakulteten, Institutionen för molekylärbiologi (Medicinska fakulteten).
Umeå universitet, Medicinska fakulteten, Institutionen för molekylärbiologi (Medicinska fakulteten). Division of Experimental Cancer Research, Department of Translational Medicine, Clinical Research Centre, Lund University, Malmö, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för molekylärbiologi (Medicinska fakulteten).
Umeå universitet, Medicinska fakulteten, Institutionen för molekylärbiologi (Medicinska fakulteten).
Visa övriga samt affilieringar
2022 (Engelska)Ingår i: Molecular Oncology, ISSN 1574-7891, E-ISSN 1878-0261Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Low-affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa) is a cell surface protein that belongs to a family of Fc receptors that facilitate the protective function of the immune system against pathogens. However, the role of FcγRIIIa in prostate cancer (PCa) progression remained unknown. In this study, we found that FcγRIIIa expression was present in PCa cells and its level was significantly higher in metastatic lesions than in primary tumors from the PCa cohort (P = 0.006). PCa patients with an elevated level of FcγRIIIa expression had poorer biochemical recurrence (BCR)-free survival compared with those with lower FcγRIIIa expression, suggesting that FcγRIIIa is of clinical importance in PCa. We demonstrated that overexpression of FcγRIIIa increased the proliferative ability of PCa cell line C4-2 cells, which was accompanied by the upregulation of androgen receptor (AR) and phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5Kα), which are the key players in controlling PCa progression. Conversely, targeted inhibition of FcγRIIIa via siRNA-mediated knockdown or using its inhibitory antibody suppressed growth of xenograft PC-3 and PC-3M prostate tumors and reduced distant metastasis in xenograft mouse models. We further showed that elevated expression of AR enhanced FcγRIIIa expression, whereas inhibition of AR activity using enzalutamide led to a significant downregulation of FcγRIIIa protein expression. Similarly, inhibition of PIP5K1α decreased FcγRIIIa expression in PCa cells. FcγRIIIa physically interacted with PIP5K1α and AR via formation of protein-protein complexes, suggesting that FcγRIIIa is functionally associated with AR and PIP5K1α in PCa cells. Our study identified FcγRIIIa as an important factor in promoting PCa growth and invasion. Further, the elevated activation of FcγRIII and AR and PIP5K1α pathways may cooperatively promote PCa growth and invasion. Thus, FcγRIIIa may serve as a potential new target for improved treatment of metastatic and castration-resistant PCa.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2022.
Nyckelord [en]
AR pathway and antibody-based therapy, FcγRIIIa receptor, PIP5K1α, prostate cancer metastasis, targeted therapy
Nationell ämneskategori
Cancer och onkologi
Forskningsämne
medicin; molekylär medicin (genetik och patologi)
Identifikatorer
URN: urn:nbn:se:umu:diva-192100DOI: 10.1002/1878-0261.13166ISI: 000745727600001PubMedID: 34932854Scopus ID: 2-s2.0-85123504907OAI: oai:DiVA.org:umu-192100DiVA, id: diva2:1634177
Forskningsfinansiär
Cancerfonden, 2017-381Vetenskapsrådet, 2019-01318Stiftelsen för internationalisering av högre utbildning och forskning (STINT), IG2013-5595KempestiftelsernaCancerforskningsfonden i NorrlandTillgänglig från: 2022-02-01 Skapad: 2022-02-01 Senast uppdaterad: 2024-03-20Bibliografiskt granskad

Open Access i DiVA

fulltext(11109 kB)168 nedladdningar
Filinformation
Filnamn FULLTEXT02.pdfFilstorlek 11109 kBChecksumma SHA-512
faea448aa7f7600ed411381d2357bca44fa2e3064b0f3cd7762d6c2d54ef8e039da0aefd9e5541620264cb0220a7de0537b4783156ef25dc94b35d6edf643eab
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Flodbring Larsson, PerKarlsson, RichardSarwar, MartuzaMiftakhova, Regina R.Wang, TianyanKhaja, Azharuddin Sajid SyedSemenas, JuliusChen, SaHedblom, AndreasAmjad, AliKumar, AnjaniWai, Sun NyuntÖhlund, DanielGrundström, ThomasPersson, Jenny L.

Sök vidare i DiVA

Av författaren/redaktören
Flodbring Larsson, PerKarlsson, RichardSarwar, MartuzaMiftakhova, Regina R.Wang, TianyanKhaja, Azharuddin Sajid SyedSemenas, JuliusChen, SaHedblom, AndreasAmjad, AliKumar, AnjaniWai, Sun NyuntÖhlund, DanielGrundström, ThomasPersson, Jenny L.
Av organisationen
Institutionen för molekylärbiologi (Medicinska fakulteten)Institutionen för molekylärbiologi (Teknisk-naturvetenskaplig fakultet)Umeå Centre for Microbial Research (UCMR)Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM)Institutionen för strålningsvetenskaper
I samma tidskrift
Molecular Oncology
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 243 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 685 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf